Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment  SARASOTA, Fla, April  29, 2026  (GLOBE NEWSWIRE) --  Silo Pharma, Inc.

SILO

Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

Silo Pharma Gains from Federal Boost for Psychedelic Therapeutics

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment  SARASOTA, Fla, April  29, 2026  (GLOBE NEWSWIRE) --  Silo Pharma, Inc.</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Silo Pharma commends U.S. federal initiatives advancing psychedelic-based therapies, enhancing its strategic position in mental health treatment. Notable funding and regulatory advancements could accelerate the company&#039;s development pipeline and improve treatment options for PTSD and other interconnected disorders.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Federal initiatives boost psychedelic-based therapeutics for mental health.</li><li>Silo Pharma supports need for innovative mental health treatments.</li><li>FDA expedited IND clearance exemplifies growing interest in psychedelics.</li><li>Funding announced for leading universities enhances competitive position in research.</li><li>New clarity on regulatory pathways expected to benefit therapeutic development.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>DemeRx NB (N/A)</strong>: Shows FDA&#039;s commitment to advancing mental health drugs.</li><li><strong>Compass Pathways (CMPS)</strong>: Recipient of National Priority Voucher; signals institutional focus on psychedelics.</li><li><strong>Usona Institute (N/A)</strong>: Gaining recognition in psychedelic research, potentially influencing funding trends.</li><li><strong>Transcend Therapeutics (N/A)</strong>: Involved in high-impact therapies, indicating a competitive landscape.</li><li><strong>Johns Hopkins University (N/A)</strong>: Leading institution in psychedelic research, enhancing the credibility of funded projects.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>This news falls under &#039;Industry News&#039; as it reflects significant federal initiatives influencing the broader psychedelic therapeutics market. Such developments are pivotal for companies like Silo Pharma engaged in mental health solutions, thus shaping market dynamics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Federal initiatives signal increased funding for psychedelic research.</li><li>FDA support for INDs may lead to market expansion for related products.</li><li>Increased focus on PTSD treatment could enhance Silo&#039;s portfolio desirability.</li><li>Government investments validate Silo’s research direction and strategic partnerships.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Silo Pharma focuses on mental health treatment using psychedelic therapies.</li><li>FDA granted IND clearance for DemeRx&#039;s alcohol use candidate recently.</li><li>Three National Priority Vouchers awarded for PTSD-relevant therapies.</li><li>EVIDENT program funds institutions like Johns Hopkins for psychedelic research.</li><li>Final guidance for psychedelic drug development will be published soon.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>SILO could see strong price appreciation as federal support accelerates growth in psychedelic therapeutics.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p><i>Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment</i></p>  <p align="justify">SARASOTA, Fla, April  29, 2026  (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SILO">SILO</a>), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today commends a wave of coordinated U.S. federal actions that are rapidly advancing the development of psychedelic-based therapeutics for mental health and substance use disorders. Building on last weekend's executive initiative to fast-track these treatments, multiple agencies have taken meaningful steps this week to accelerate research, clinical progress, and regulatory clarity across the sector.</p>  <p align="justify">The Advanced Research Projects Agency for Health announced initial awardees under its EVIDENT program, including leading institutions such as Johns Hopkins University and other innovators focused on psychedelic science. Silo believes this funding validates its position on the growing importance of data-driven approaches to treating complex neurological and psychiatric conditions.</p>  <p align="justify">In parallel, the U.S. Food and Drug Administration granted investigational new drug (IND) clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder, highlighting continued expansion of clinical-stage programs in the mental health space.</p>  <p align="justify">"We are witnessing a coordinated and accelerating shift at the federal level," said Silo CEO Eric Weisblum. "From funding and clinical advancement to regulatory prioritization, in our opinion the foundation is being laid for a new generation of therapies that could transform how we treat PTSD and related disorders."</p>  <p align="justify">The FDA issued three Commissioner's National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics, underscoring a clear intent to accelerate high-impact therapies. Notably, the inclusion of a PTSD-relevant program further signals a strong institutional focus on addressing urgent unmet needs among veterans and broader patient populations. Additionally, the organization confirmed that final guidance for psychedelic drug development will be published imminently, a long-anticipated milestone expected to provide critical clarity for sponsors and researchers navigating clinical and regulatory pathways.</p>  <p><b>About Silo Pharma, Inc.</b></p>  <p>Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease. Silo's research is conducted in collaboration with leading universities and laboratories. <a href="https://www.globenewswire.com/Tracker?data=Yx6Suo5rOcx0mgoyYk_hMtxk09WoRXys1nHiorKwNa9tYODo_AT9vEiqVEwSAGzcICmfuOam8bOl27te3JR_QgTo-yq2lPgijGHRb-n4kQC2DnjBSmAwb0miU9tsdLyn2VkTwdmpoCW3v163NO2YYvlV-ksp4wqf7TlqM17SBovufHDitIu87hy4aKSroR33E5sRB3khwh48BLuUFgZfZxpu80qFC9MBPOfEenhgVKkq4HueRrJRlVD1qa2MRxibILB0KNPB5IuGMDT1tWIoacyWDOveMujAZuvsoJZuntO-jijWuncrOraMLGMqzw0qzSttInZwz4bHR4_GJRwR-wq5b0ztNkn3ze1Bj2eyfCEhl_0w2ZFxIq_HsP5Hhp5Tqo8ePokf42kFysNP4VCA1ZIky90FNSTJvkz0xOoTZbkp8cjQ3Qw6A2AjoEDxovlF2F9NERSxZyEONmEoHV02g98AI5ORE2i68NPFSYm3gvW4mbfXn2rVA2Vtq26cQ-C203HQY7xT1nmtWVg3YrvMvCo1eGliquOaX5OTie3JfVplkDHudem_LFYUg53Ritr-K2Ud0TFfcZvG_LhaAQab4VQce0PBNvpSvAq0_Zo5AG3c0WHHT_7EyAEKwe9ufJ4qgJZj9mcZBE1BvMvuyLFXmW1JjGfA4UiEKkfuCANvzow=" rel="nofollow" target="_blank">silopharma.com</a></p>  <p><b>Forward Looking Statements</b></p>  <p>This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential", and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.</p>  <p><b>Contact</b></p>  <p>(800) 705-0120<br></br><a href="https://www.globenewswire.com/Tracker?data=0KleTZdSYQbsu6B7WVYla-ck_DylYNVhl3N8EqM5Pt_QIJRlnpAUgVCCC449uR-L3Z6qRprQqvRvNYsJqirqpyHzZmT51jJM4KmE5VQI1_tXShiL1TdJzN9JQQx8c-AjptMMTmkfp2PyXkKdCRQr8s6ggWA-1ezUTaseLYPiQT7lSPiXIMsZ5iG0e_t3wnzu1mrWyU7OR99M_Fzh9YZ1cp0LICY4FNTLLpO8Jl0y0x749SBXdxO_OxwHxhc69KXqG_zi2CM8J-4N0IrqbLJqOGA81goIVrSBMsAp8k55de8=" rel="nofollow" target="_blank">investors@silopharma.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcwOTA3OSM3NTcxODcwIzUwMDA2OTMzOQ=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YTBkZjEzYWUtZTQ2YS00YjE1LWE5ZjUtZTVmODYxNjM3OWI3LTUwMDA2OTMzOS0yMDI2LTA0LTI5LWVu/tiny/Silo-Pharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b635464-4382-4b8b-8175-39cc32e08050"><img src="https://ml.globenewswire.com/media/3b635464-4382-4b8b-8175-39cc32e08050/small/logo-png.png" border="0" width="150" height="73" alt="Primary Logo"></img></a></p>

Silo Pharma commends U.S. federal initiatives advancing psychedelic-based therapies, enhancing its strategic position in mental health treatment. Notable funding and regulatory advancements could accelerate the company's development pipeline and improve treatment options for PTSD and other interconnected disorders.

Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News